MannKind Corporation Participation at Upcoming Conferences

[letitride]

Over the years having had my own business, people would come to me and say Im going to start a business. My reply was always the same that takes balls, but staying in it may require much bigger ones. Kind of like investing in Mannkind!

[diski58]

Jan 12, 2024 12:28:37 GMT -5 wmdhunt said:

With PED approval looking like April of 2025, at the earliest) MNKD will take another nap I'm sorry to say. So many struggles and our lenders shorting the stock every chance they get, what can MNKD possibly do? It seemed the Morgan Stanley thingy was only attended by 2 or 3 actual humans. The applause was obviously only a couple of folks. So disappointing.

Attachments:

[sayhey24]

Jan 12, 2024 13:45:21 GMT -5 letitride said:

The only quick solution is M&A. As the price drops and the stability and potential continue to evolve the threat of either to short positions becomes more real. Mike has optionality and with the closing of the most recent deal should not be ruled out. I to have optionality and at these prices am looking how to best use them.

Before M&A the Board needs to make a decision - do they want to continue with afrezza.  This is a major decision which needs to be made before looking to merge.

I think I heard Mike say yesterday that we have new leadership (again) heading up the Edno (afrezza) division.  I am guessing that is Matthew Nguyen.  I am not sure we got a press release on this.  It seems Mr. Nguyen came with the V-Go deal but I am just guessing.  If so I wonder if he really understands the power of afrezza and why afrezza and V-Go are like oil and water.

So what happened to the last guy?  Was he not able to turn around V-Go and we put a V-Go guy in charge to make this our shinning star?

At this point we keep doing the same thing over and over and then we blame the sales people.  Four things have held back afrezza; the label; the studies to change the label; the SoC which Dave Kendall was going to fix; and insurance coverage.  The first three we can control.  The last one not so much.

I was recently reading how a number of insurance companies are further squeezing afrezza insurance companies.  One example is Kaiser.  Even though 2023 seems like a pretty good year for them they are cutting back what better place to reduce than afrezza coverage.

As some history on Sanofi - they were not the original partner.  They swooped in at the end and did the deal but as soon as Viehbacher inked the deal he was shown the door for Brandicourt who knifed afrezza day 1.  If Viehbacher was not canned things would have been a lot different.  Then again, did Viehbacher expect to be canned?  I don't think so as I think Al Mann was caught off guard and I doubt he would have ever done the deal with Brandicourt.

I think at this point the Board either needs to go all in and fish or cut bait.  We are not getting insurance coverage.  No one is going to pay $500 a box let alone $1k a box.  When the kids get approved there won't be any insurance coverage and this huge expected surge in scripts is not going to happen.  When the Cipla results come in we might as well throw them in the trash as no one can afford it at $1k a box.  Maybe Mr. Nguyen has a plan for how he is going to make afrezza affordable.  If so I would love to hear and see it.  Otherwise its time to cut bait and put more V-Gos in the reps bags until that too proves to be a failure.  I doubt we will ever find an M&A partner for V-Go.

[prcgorman2]

As you mentioned in a recent post, small margins are OK if you can make it up in volume. There is more than one way to get the price down but there has to be concomitant increase in volume (prescriptions) and that requires breaking down prescriber reluctance and that requires acceptance Afrezza is SAFER and more effective. The Pediatric trial is the first real salvo in getting that message across, but doesn't have to be the last. Assuming available operating capital increases sufficiently over time, full scale, multi-arm study can in theory proceed. Tyvaso DPI was the lucky break but what can be made from it can be earned and require less luck.

[castlerockchris]

I am pretty sure management and the board have clearly decided to fish. How many Afrezza studies does MNKD have going right now - 2? One significant trial - Peds. You don't spend millions on this stuff if your intentions is to cut bait. As for insurance, I would bet they are working on that - not sure if they will be successful or not. Again, you don't spend millions on studies and drug trials without recognizing that insurance will be a driver of your success, unless you feel you can knock the price down to where insurance coverage isn't needed. No way has MC and his team worked this long and this hard on Afrezza without the understanding that insurance coverage is one of the long poles in the tent.

Also, I am pretty sure we should not measure the medical insurance world by Kaiser, which having first hand experience with, is far and away the worst health insurance company I have ever paid to abuse me. If you want to see what single payer/socialized medicine is like, become a Kaiser subscriber. They SOP is scarcity and "we can see you in a 3 months" if you are looking for a specialist. Heck don't get a sever cold or flu because your primary doctor can't fit you in for two to three weeks, so good luck suffering. In addition, once you do get in to see a doctor or a specialist, they refuse to address multiple symptoms or presentations, forcing you to run the gauntlet again.

Somebody help me, but I thought I heard MC say during the JPM presentation that they had restructured the sales team and moved some of the team away from selling and more into a "coach" or patient training role? Did I get that wrong? If I heard correctly, that would mean MNKD is learning and taking a page from VDEX's playbook...not a bad thing.

 Quick Edit - I have studied micro economics and finance in my post graduate work and in the real world and I will take high margins on fewer sales vs. low margins and try to make it up on volume any day of the week. Less production capacity required, less overhead, less of everything, expect profit. Look at AAPL vs Samsung or Moto as my guide. This talk of going nuclear is a game where MNKD will lose. It assume price is the only factor in a purchase decision. I would rather sell 1,000 widgets per month at $1,000 (i.e. higher margin) than have to sell 5,000 widgets per month at $200.

[sayhey24]

Jan 12, 2024 16:29:12 GMT -5 prcgorman2 said:

As you mentioned in a recent post, small margins are OK if you can make it up in volume. There is more than one way to get the price down but there has to be concomitant increase in volume (prescriptions) and that requires breaking down prescriber reluctance and that requires acceptance Afrezza is SAFER and more effective. The Pediatric trial is the first real salvo in getting that message across, but doesn't have to be the last. Assuming available operating capital increases sufficiently over time, full scale, multi-arm study can in theory proceed. Tyvaso DPI was the lucky break but what can be made from it can be earned and require less luck.

I am not sure I am explaining this properly.  No one is paying $500 a box let alone $1k and BP will do whatever needs to be done to marginalize afrezza sales.  Right now for them its a cake walk - get the insurers not to cover it and point the doctors at the label and then have them fill out appeal after appeal after appeal so that they don't want the hassle of prescribing afrezza.

The kids study is going to be great - and then what?  We will get some mention in the SoC (in parenthesis).  The kids will get approved and because it will have near zero insurance coverage they won't be able to afford it.  Unless we can fix the insurance issue prior and get it so price is not a barrier, the kids study is a waste of time.  It won't be the salvo across the bow, it will be the tree falling in the forest that no one hears.

At one point Mike was going to solve this problem and provide afrezza for $99.   Maybe $99 is still too high and $35 is better but thats a lot better than $1k.  OK - here is the website  afrezza.com
Tell me how I get my afrezza for $99?  Its out there if you look hard enough.  Is it me or is it hard to find?  Maybe I am an idiot.  I use to be able to go to insulinsavings.com and order.  That is gone.  Why?

Can Mr. Nguyen fix the price of afrezza?  He better or I will give him some advice - DO NOT unpack your boxes.  If Mr. Nguyen wants to keep his job he better go straight to Mike and the Board and tell them he needs that $70M Mike is planning on spending on Icon-1 for a last ditch effort to save afrezza.  If not he should just tell them to save the money on the kids study and everything else associated with afrezza and just shut her down. 

[sayhey24]

Jan 12, 2024 18:40:37 GMT -5 castlerockchris said:

I am pretty sure management and the board have clearly decided to fish. How many Afrezza studies does MNKD have going right now - 2? One significant trial - Peds. You don't spend millions on this stuff if your intentions is to cut bait. As for insurance, I would bet they are working on that - not sure if they will be successful or not. Again, you don't spend millions on studies and drug trials without recognizing that insurance will be a driver of your success, unless you feel you can knock the price down to where insurance coverage isn't needed. No way has MC and his team worked this long and this hard on Afrezza without the understanding that insurance coverage is one of the long poles in the tent.

Also, I am pretty sure we should not measure the medical insurance world by Kaiser, which having first hand experience with, is far and away the worst health insurance company I have ever paid to abuse me. If you want to see what single payer/socialized medicine is like, become a Kaiser subscriber. They SOP is scarcity and "we can see you in a 3 months" if you are looking for a specialist. Heck don't get a sever cold or flu because your primary doctor can't fit you in for two to three weeks, so good luck suffering. In addition, once you do get in to see a doctor or a specialist, they refuse to address multiple symptoms or presentations, forcing you to run the gauntlet again.

Somebody help me, but I thought I heard MC say during the JPM presentation that they had restructured the sales team and moved some of the team away from selling and more into a "coach" or patient training role? Did I get that wrong? If I heard correctly, that would mean MNKD is learning and taking a page from VDEX's playbook...not a bad thing.

 Quick Edit - I have studied micro economics and finance in my post graduate work and in the real world and I will take high margins on fewer sales vs. low margins and try to make it up on volume any day of the week. Less production capacity required, less overhead, less of everything, expect profit. Look at AAPL vs Samsung or Moto as my guide. This talk of going nuclear is a game where MNKD will lose. It assume price is the only factor in a purchase decision. I would rather sell 1,000 widgets per month at $1,000 (i.e. higher margin) than have to sell 5,000 widgets per month at $200.

Have you ever gone fishing and no bites, nothing.  The guy next to you is pulling in fish after fish.  Why?  Maybe you have the wrong bait.  Afrezza at $1k is the wrong bait.

I did not hear about the "coaching role"  I will list again but the guy who is heading this up is the V-Go guy?  And he is coaching me on what?

MNKD may lose going nuclear but the have the nuclear bomb.  Nearly no one does but MNKD does.  If they don't and BP keeps them marginalized they have zero chance.  Look at AAPL - they disrupted the industry with the Mac after failing with the Lisa, why?  They cut the price so people could afford it and made networking so simple while bundling the apps.  

[lennymnkd]

You can discuss this every which way / Afrezza isn’t going to work without a direct to the pubic advertisement. Which the “PRODUCT is Taylor made .
A hurt them to help them style add .! Force the insurance companies to pay thur public awareness…demand ..worth leveraging the whole operation for .

[sayhey24]

I have time to go back and Zapruder the presentation. I thought it was an excellent presentation from a standpoint of bringing the public up to date on current activities and plans. I also heard Mike address some specific concerns raised on this board.

For MK 101 - they completed the initial powder formulation. I think thats great news.

For V-Go - Discipline selling of V-Go to secondary position to maintain core subscribing base. Rebates and discounts are being "reduced". This I find as an interesting statement and one predicted last year on this board. I think this is great news too.

For afrezza - Mike said - "We can't keep doing the same thing over again". I will add "over and over and over again and expect different results". We cut back on sales reps to key account reps. The reimbursement and training people are still there. He mentioned GLP1s numerous times and the afrezza focus is T1 as not to compete with GLP1s (in other words - BP). We have developed "new messaging". We have no new plan to deal with the main blocker - insurance but we are going to get better at handling the paperwork to get coverage. For afrezza, aside from cutting back on reps and getting more "disciplined" selling V-Go into our key afrezza accounts not much has changed. There was no update on the India Study and its not on the 2024 Milestone slide which I find concerning.

[hopingandwilling]

You posted: They completed the initial powder formulation---that is great news! 

But don't you remember the CEO was boasting that their "vials" of new clofazimine were coming off the assembly line in Danbury. This was nearly three months ago!

Apparently, you have forgotten that they have done a Phase I study involving canine patients, where they were dosed with clofazimine via a nebulizer. 

You do remember the German plant was damaged by fire, thus disrupting them getting the needed supply of clofazimine, but when you search for such a German fire, you find Midas Pharma located in Ingelheim, Germany as the certified manufacture of clofazimine.  www.midas-pharma.com/en/latest-activities/midas-pharma-obtains-cep-for-clofazimine/
In fact, when you do a search for a fire in a German drug manufacturing plant, at the time MannKind announced such an event, one can't find such an event.

But what is more interesting is when you search for a manufacture of Clofazimine in India, you find what might be the largest supplier of clofazimine. The real question is whether the India drug delivery for their citizens, will they opt to pay for a pill dosage or a more expense nebulizer dose. For that matter, what will the total Asian drug delivery system pay for the more expensive nebulizer product? Then you have the EU nations with a standardized approval process for approving new drugs for their countries. Having price controls being a major factor.  Never forget, Novartis has the patent for the only formal approved clofazimine drug being on the market--Lamprene. NOVARTIS stopped trying to market the drug, but they have an agreement with WHO to make the drug available in their nations.  So, in reality the worldwide market is going to be the United States, and if any company understands how our insurance system works when it comes to the price of a drug--that should be MannKind. Let me repeat--MannKind with Afrezza should be a good indicator for the pricing of a drug, if they want it paid for via our insurance gatekeepers.

What would be great news is that MannKind formally announces they have launched their adaptive FDA approval clinical trials that has been pending for 12 months since they announced the need for their adaptive process clinical trial. Plus, it appears MannKind has indicated they will need 200 patients for this trial, but one should ponder how long it will take to fully enroll such a number of patients.

There is no doubt that clofazimine has shown efficacy against bacterial infections, and clofazimine has been available but there have been no takers that will support the cost of manufacturing and distribution to the end user.

[hellodolly]

Jan 13, 2024 13:04:21 GMT -5 hopingandwilling said:

You posted: They completed the initial powder formulation---that is great news! 

But don't you remember the CEO was boasting that their "vials" of new clofazimine were coming off the assembly line in Danbury. This was nearly three months ago!

Apparently, you have forgotten that they have done a Phase I study involving canine patients, where they were dosed with clofazimine via a nebulizer. 

You do remember the German plant was damaged by fire, thus disrupting them getting the needed supply of clofazimine, but when you search for such a German fire, you find Midas Pharma located in Ingelheim, Germany as the certified manufacture of clofazimine.  www.midas-pharma.com/en/latest-activities/midas-pharma-obtains-cep-for-clofazimine/
In fact, when you do a search for a fire in a German drug manufacturing plant, at the time MannKind announced such an event, one can't find such an event.

But what is more interesting is when you search for a manufacture of Clofazimine in India, you find what might be the largest supplier of clofazimine. The real question is whether the India drug delivery for their citizens, will they opt to pay for a pill dosage or a more expense nebulizer dose. For that matter, what will the total Asian drug delivery system pay for the more expensive nebulizer product? Then you have the EU nations with a standardized approval process for approving new drugs for their countries. Having price controls being a major factor.  Never forget, Novartis has the patent for the only formal approved clofazimine drug being on the market--Lamprene. NOVARTIS stopped trying to market the drug, but they have an agreement with WHO to make the drug available in their nations.  So, in reality the worldwide market is going to be the United States, and if any company understands how our insurance system works when it comes to the price of a drug--that should be MannKind. Let me repeat--MannKind with Afrezza should be a good indicator for the pricing of a drug, if they want it paid for via our insurance gatekeepers.

What would be great news is that MannKind formally announces they have launched their adaptive FDA approval clinical trials that has been pending for 12 months since they announced the need for their adaptive process clinical trial. Plus, it appears MannKind has indicated they will need 200 patients for this trial, but one should ponder how long it will take to fully enroll such a number of patients.

There is no doubt that clofazimine has shown efficacy against bacterial infections, and clofazimine has been available but there have been no takers that will support the cost of manufacturing and distribution to the end user.

Lots of information packed into this post that I'll untie and separate into their respective replies:

You posted: They completed the initial powder formulation---that is great news! It is terrific news as some here had wondered if MNKD was going to have a DPI version.  On slide 17 of the JPM presentation, that question was answered.  The name of the trial ICoN-1,  regardless if they identified a formulation for DPI to treat NTM or not, the decision to move ahead with the nebulizer version at this time makes sense based on the efficacy of MNKD-101 which so far in their human trials has shown to be effective because it presents low systemic exposure, localized concentrations in the lungs and less side effects.  Now, let's talk about the side effects for a second.  Mike mentioned that the current oral dose of clofazimine has such horrible side effects, requires "regimens that take patients anywhere from 18 months to five years" and that even with people who have a life expectancy of five years once diagnosed with NTM, they would rather die and not take the drug because the side effects are terrible and "exacerbate their poor quality of life."  So, to that end..it makes sense to go with the nebulizer version as the other versions are no doubt very efficacious, but intolerable and "patients just give up."  Finally, the nebulizer version of MNKD-101 is able to "cut the dose by 80%...that is delivered directly to the lungs...to kill the bug in the lung with our suspension." 

This puts to bed the questions on this board as to which way MNKD is going with MNKD-101.  Will the DPI version come around at some point? It seems they at least want to evaluate it, "We'll look at moving the dry powder formulation forward because if we want to compete with early naive patients, it will be good to have that moving forward." 

You posted: But don't you remember the CEO was boasting that their "vials" of new clofazimine were coming off the assembly line in Danbury. This was nearly three months ago!  Ah, yes the time it takes to bring a drug to market doubt, a la garden variety style.  LOL, a whopping three whole months ago surely must mean something? Jesus, Joseph and Mary!  Are these people sitting on their hands at MNKD?  My decades old biotech investing spidey senses tell me it means that they're going through the regulatory processes, i.e.; working towards filing the IND, identified 70 trial sites so once approved they can get going and working with their CRM in order to identify and optimize processes for targeting endpoints in the trials.  Whoa.  Get ready for the trials, they take longer.

You posted: In fact, when you do a search for a fire in a German drug manufacturing plant, at the time MannKind announced such an event, one can't find such an event.  Not unusual to be unable to find events on the Internet.  I couldn't find anything AND it doesn't mean anything. Where are you leading the reader?

You posted: So, in reality the worldwide market is going to be the United States, and if any company understands how our insurance system works when it comes to the price of a drug--that should be MannKind. Let me repeat--MannKind with Afrezza should be a good indicator for the pricing of a drug, if they want it paid for via our insurance gatekeepers. Why yes, we are all very familiar with the insurance system and pricing of diabetes drugs.  That's what you are talking ab out, indirectly.  But, to infer that MNKD won't have any success with marketing and commercializing MNKD-101 due to insurance is premature and lacks merit since you are focused on the endocrine space and MNKD 101 is in the orphan lung space.  Apples and oranges, yet both are round doesn't make the insurance issue, an issue.  If anything, we have a better chance of comparing the success of MNKD-101 with TYvaso, DPI  based on the connection with UTHR, also focused on orphan lung diseases and with the fact that Clofazimine is a well known drug by doctors who treat these patients. Insmed, the supplier of ARIKAYCE, a current treatment for NTM, are all too familiar with regimen issues and patient drop offs. The Orphan drugs also offer at least 12 years of exclusivity from time of approval and the CAGR is roughly 5.66% by 2028 and worth globally about $4.33 BILLION. Source: finance.yahoo.com/news/nontuberculous-mycobacterial-infections-market-size-041500732.html

Finally, comparing Afrezza and MNKD-101 before trials are even completed is a fools errand.  You can speculate based on prior diabetes industry giants having a stranglehold on the market, regardless if they have their foot on the neck of MNKD (toss it away), the competition in the NTM space is about nil.  In fact, my hunch is that BP would love to have MNKD go and focus on something else, entirely.  Maybe that's the direction they're headed but, not without going down with at least a few more tricks up their sleeve, i.e.; INHALE 1 and INHALE 3, India.  MNKD is the gift that keeps on giving to BPs left nut, like dog pecker gnats, just won't go away.

You posted: What would be great news is that MannKind formally announces they have launched their adaptive FDA approval clinical trials that has been pending for 12 months since they announced the need for their adaptive process clinical trial. Plus, it appears MannKind has indicated they will need 200 patients for this trial, but one should ponder how long it will take to fully enroll such a number of patients.  Dude, you are commingling the story and jumping back and forth.  Can you elaborate on the question you have asking readers to ponder how long it will take to fully enroll such  number of patients?  Give us your best guess how long the average enrollment should be for 200 patients in this trial, based on your knowledge of the number of trial sites and locations.  Personally, they get it done when they get the 200 participants but, they can begin dosing on day one with the first patient and don't have to wait for 200 to get it started.  It only means they could add to the back end of the trials length.  Not uncommon in any trial research.  Barriers to enrollment, screening failures and more account for over 80% of the trials are delayed or closed entirely. Source: www.antidote.me/blog/what-clinical-trial-statistics-tell-us-about-the-state-of-research-today

You posted: There is no doubt that clofazimine has shown efficacy against bacterial infections, and clofazimine has been available but there have been no takers that will support the cost of manufacturing and distribution to the end user. OK, back to NFM and MNKD-101.  Well, we do know that MNKD has been in discussions with Japanese regulators about MNKD-101 as the research shows that there are roughly 100,000 people afflicted with this horrible disease in the eastern Asia population, namely Japan.  My bet South Korea, too.  Do you think it is wise and prudent to discuss any partnerships without establishing a bona fide contract, just in case there are lingering questions by either countries regulatory bodies? 

I'm certain, without a doubt, that MNKD has in mind a partner, someone who is big into the orphan lung space industry and once the ink is dry on the BLA, there will be some sort of announcement, if not before this.  Just my thoughts on your thoughts.

[lennymnkd]

Jan 12, 2024 19:28:59 GMT -5 lennymnkd said:

You can discuss this every which way / Afrezza isn’t going to work without a direct to the pubic advertisement. Which the “PRODUCT is Taylor made .
A hurt them to help them style add .! Force the insurance companies to pay thur public awareness…demand ..worth leveraging the whole operation for .

Especially pediatrics , when the day comes !

[sayhey24]

Jan 13, 2024 13:04:21 GMT -5 hopingandwilling said:

You posted: They completed the initial powder formulation---that is great news! 

But don't you remember the CEO was boasting that their "vials" of new clofazimine were coming off the assembly line in Danbury. This was nearly three months ago!

Apparently, you have forgotten that they have done a Phase I study involving canine patients, where they were dosed with clofazimine via a nebulizer. 

You do remember the German plant was damaged by fire, thus disrupting them getting the needed supply of clofazimine, but when you search for such a German fire, you find Midas Pharma located in Ingelheim, Germany as the certified manufacture of clofazimine.  www.midas-pharma.com/en/latest-activities/midas-pharma-obtains-cep-for-clofazimine/
In fact, when you do a search for a fire in a German drug manufacturing plant, at the time MannKind announced such an event, one can't find such an event.

But what is more interesting is when you search for a manufacture of Clofazimine in India, you find what might be the largest supplier of clofazimine. The real question is whether the India drug delivery for their citizens, will they opt to pay for a pill dosage or a more expense nebulizer dose. For that matter, what will the total Asian drug delivery system pay for the more expensive nebulizer product? Then you have the EU nations with a standardized approval process for approving new drugs for their countries. Having price controls being a major factor.  Never forget, Novartis has the patent for the only formal approved clofazimine drug being on the market--Lamprene. NOVARTIS stopped trying to market the drug, but they have an agreement with WHO to make the drug available in their nations.  So, in reality the worldwide market is going to be the United States, and if any company understands how our insurance system works when it comes to the price of a drug--that should be MannKind. Let me repeat--MannKind with Afrezza should be a good indicator for the pricing of a drug, if they want it paid for via our insurance gatekeepers.

What would be great news is that MannKind formally announces they have launched their adaptive FDA approval clinical trials that has been pending for 12 months since they announced the need for their adaptive process clinical trial. Plus, it appears MannKind has indicated they will need 200 patients for this trial, but one should ponder how long it will take to fully enroll such a number of patients.

There is no doubt that clofazimine has shown efficacy against bacterial infections, and clofazimine has been available but there have been no takers that will support the cost of manufacturing and distribution to the end user.

I think Dolly did a great job of responding to you.  Do you have additional questions?

I still think it is great that they finally figured out how to make it work for DPI.  After listening to the UTHR presentation DPI is the way to go.  With the fire delay it would have been nice to switch to DPI and not have to do additional trials.  I think if DPI was ready they would have.  At this point it is what it is.  Personally I would be OK delaying the $70M spend a little longer to give afrezza a real shot at realizing its potential but Mike clearly does not want to poke the bear.  He said numerous times how afrezza for T1s  will not impact GLP1s, in other words lets not get BP upset.  My thinking is different.  I would take my old school Winchester 30-30 and shoot the bear right between the eyes.  It is what it is at this point.

What is also clear is while Mike pulled out Al's old file of things they were looking at,Clofazimine won over Glp1s.   My guess is BP could care less about Clofazimine but come out with a Saxenda DPI and that big old bear will surely wake up and Mike at the time did not have the Winchester.  However now he has a nuclear bomb and with Saxenda DPI he would have 2 - both Fat Man and Little Boy. 

[sayhey24]

Jan 13, 2024 17:16:21 GMT -5 lennymnkd said:

Jan 12, 2024 19:28:59 GMT -5 lennymnkd said:

You can discuss this every which way / Afrezza isn’t going to work without a direct to the pubic advertisement. Which the “PRODUCT is Taylor made .
A hurt them to help them style add .! Force the insurance companies to pay thur public awareness…demand ..worth leveraging the whole operation for .

Especially pediatrics , when the day comes !

They need to figure out this insurance blockage before the kids get approved.  Otherwise we are doing what we have doing for years and just spitting in the wind.  Maybe we will get two mentions in the SoC for the kids (both in parentheses).

If and when Mike wants to get serious we need more than DTCA.  We need an army of "thought leaders", a team of DC lawyers, a campaign fund plus the DTCA.  Most of all we need  proper afrezza pricing.

[lennymnkd]

No sales reps / no advertising … how does this get done ..what am I missing/ business 101